Rimoni Industries


We operate a fully equipped clean room and adheres to the highest production standards, including ISO 13485 (with Clean Room ISO 8 = class 100000) for Medical Devices & Hygienic parts.



A non-invasive sugar testing device

The Cnoga All-In-One device enables the measurement of 15 biomedical parameters in a non-invasive manner, including blood sugar levels. Matched with the cloud platform, Cnoga allows telemedicine anytime, anywhere.
The demand was to design and plan the company's next generation of products. The project included research and study of user requirements and product analysis.
The design challenge was to create an easy to use and professional "non-medical" device, with an inviting look.
The planning challenge was to produce a product that enables accurate testing, with limited volume and weight. The design included PCB, screen and more.


By Tempramed

VIVI CAP1 is a replacement cap for insulin pens

MyVivi is designed to keep insulin cool within safe temperatures below 29°C (84.2°F) for a minimum of 12 hours, even in a constant environmental temperature of 37.8°C (100°F), when the device is placed inside a personal handbag.
How does it work?
The cap temperature regulation is passive and combines thermal insulation with heat absorbent material. The cap is ‘reactivated’/filled up’ to provide safe storage conditions, whenever the ambient temperature drops below 26°C (78.8°F), for subsequent periods of 12 hours and for up to 365 days of continuous daily use.
The customer's demand was to design a simple but identifiable product, "... that won't roll off the table...".
We overcame some planning and designing challenges, such as providing a solution for a series of products, designated not only for different types of insulin injectors but also for other products.
The engineering design included the packaging of electronic and metal components, sealing of liquids and mechanical adjustment of each type of syringe.


By colospan

Protection against leaks in colorectal surgery

A colorectal leak is the most serious complication of colorectal surgery. The leak may occur after the removal of an intestinal segment and the connection of two healthy parts.
Cologuard developed a device that provides protection against leaks in colorectal surgery, thus dramatically reducing patient suffering and even death, as well as cutting medical expenses.
The design and development challenge was to create an intuitive operating handle for the doctor, thus minimizing confusion or hesitation while operating, by providing clear indications and simple and reliable design.

TEVA adaptors

By Teva

Teva has been working with Rimoni for over 20 years, mainly in manufacturing molds for a variety of components, from single-socket molds to commercial injection from multi-socket molds. The challenge of working with Teva was adhering to short cycle times and production of millions of components per year.
The ability to grow with the customer was a very important factor in communication between companies.


By Activeimplants

Meniscus Implant

Investigational NUsurface®Meniscus Implant is the first “artificial meniscus” designed to replace one that is damaged or deteriorated. Meniscus replacement has the potential to fill the gap between minimally invasive meniscus repair and total knee replacement.
The difficulty was moving from a slow and unstable production process based on development patterns, to an automatic and repeatable production process.
The NUsurface® implant is made from polycarbonate-urethane (PCU) – a medical grade plastic. As a result of its unique materials and composite structure and design, it does not require fixation to bone or soft tissues. The NUsurface Implant mimics the function of the natural meniscus and redistributes loads transmitted across the knee joint.
The NUsurface Meniscus Implant has been used in Europe under CE Mark since 2008 and Israel since 2011. The SUN and VENUS U.S. clinical trials completed enrollment in June 2018, and Active Implants is expecting to file for regulatory approval in the U.S. in the next two years.

Skip to content